产品管线

原启生物聚焦全球肝癌、卵巢癌、胃癌、宫颈癌、非小细胞肺癌等未被满足的临床治疗 需求,开发产生了数十个自主创新主要靶向实体瘤的细胞药物和单/双特异性抗体管线。 其中,6项肿瘤免疫细胞治疗产品已经获得了医院伦理审批,进入探索性临床开发阶段。 启动4个产品的临床注册申报工作,首个产品的申报资料将在2022年第一季度递交, 其他的3个产品的IND申报工作正在有序开展中。

CAR-T产品管线
原启生物所属权开发管线 原启生物对外合作开发

Cell Therapy
Programs
Indication
POC
IND
Phase I
Phase II/III
IP
Ori®-C101
HCC
Global
Ori®C604
MM
Global
Ori®CAR-017
R/RMM
Global
Ori®C321
R/RMM
Global
Ori®C613
Solid Tumor
Global
Ori®C615
Solid Tumor
Global
Ori®C623
Solid Tumor
Global
Ori®C624
Solid Tumor
Global
Ori®C632
NSCLC
Global

UCAR产品管线

Cell Therapy
Programs
Indication
POC
IND
Phase I
Phase II/III
IP
Ori®U629
R/RMM
Global
Ori®U607
ALL
Global

抗体产品管线

Antibody
candidate
Target
Indication
Discovery
Optimization
Preclinical
IND
Enabling
IND
Phase I
Phase II/III
IP
Ori®-Bs-001
PD-L1/4-1BB
Solid tumor
Candidate fully validated (Partnered to Antengene)
Global
Ori®A236
4-1BB
Solid tumor
Candidate fully validated
Global
Ori®A214
PD-L1
Solid tumor
Candidate fully validated
Global
Ori®A626
PVRIG
Solid Tumor
Candidate fully validated
China
Ori®A611
TIGIT
Solid tumor
Candidate fully validated
Global
Ori®A610
PD-L1/TIGIT
Solid tumor
Candidate fully validated
Global
Ori®A364
PD-L1/CLDN 18.2
Solid tumor
Candidate fully validated
Global
Ori®A362
4-1BB/CLDN 18.2
Solid tumor
Candidate fully validated
Global
Ori®A631
CD73/CD39
Solid Tumor
Candidate fully validated

CAR-T产品管线
原启生物所属权开发管线 原启生物对外合作开发

Ori®-C101

Indication: HCC

IP:Global

Ori®C604

Indication: MM

IP:Global

Ori®CAR-017

Indication: R/RMM

IP:Global

Ori®C321

Indication: R/RMM

IP:Global

Ori®C613

Indication: Solid Tumor

IP:Global

Ori®C615

Indication: Solid Tumor

IP:Global

Ori®C623

Indication: Solid Tumor

IP:Global

Ori®C624

Indication: Solid Tumor

IP:Global

Ori®C632

Indication: NSCLC

IP:Global

UCAR产品管线

Ori®U629

Indication: R/RMM

IP:Global

Ori®U607

Indication: ALL

IP:Global

抗体产品管线

Ori®-Bs-001

Target: PD-L1/4-1BB

Indication: Solid tumor

IP:Global

Ori®A236

Target: 4-1BB

Indication: Solid tumor

IP:Global

Ori®A214

Target: PD-L1

Indication: Solid tumor

IP:Global

Ori®A626

Target: PVRIG

Indication: Solid Tumor

IP:China

Ori®A611

Target: TIGIT

Indication: Solid tumor

IP:Global

Ori®A610

Target: PD-L1/TIGIT

Indication: Solid tumor

IP:Global

Ori®A364

Target: PD-L1/CLDN 18.2

Indication: Solid tumor

IP:Global

Ori®A362

Target: 4-1BB/CLDN 18.2

Indication: Solid tumor

IP:Global

Ori®A631

Target: CD73/CD39

Indication: Solid Tumor

IP: